title: Treatment of murine CD5- B cells with anti-Ig, but not LPS, induces surface CD5: two B-cell activation pathways.
abstract: Anti-Ig stimulated murine B cells express high levels of surface CD5 (ly-1) and increased CD44 while maintaining surface IgD, CD23 and J11d. Sorting of CD5- and CD5+ cells demonstrates that anti-Ig induces CD5 expression rather than the selective expansion of CD5+ cells. Anti Ig plus interleukin-6 (IL-6) induces the CD23, IgD, low ly-5 (B220) (CD45low), J11dhigh phenotype of typical CD5+ peritoneal B cells. In contrast, lipopolysaccharide (LPS)-stimulated B cells have high levels of CD44 but decreased surface IgD, CD23 and J11d and no CD5. Thus LPS and anti-Ig generate activated cells with differing phenotypes. Induced CD5+ cells have increased viability, even in the absence of added exogenous factors, while the viability of CD5- B cells is dependent on factors such as IL-4. We conclude that conventional CD5- B cells can be activated by either of two pathways: one generating CD5+ B cells; the other yielding conventional activated cells. We hypothesize that the first path requires slg cross-linking and corresponds to T-independent (type 2) stimulation, while cognate interaction with helper T cells in the absence of slg cross-linking induces B cells to enter the second path.
authors.affiliation: Department of Pathology, Tufts University School of Medicine, Boston, MA 02111.
authors.forename: Y Z
authors.initials: YZ
authors.lastname: Cong
authors.forename: E
authors.initials: E
authors.lastname: Rabin
authors.forename: H H
authors.initials: HH
authors.lastname: Wortis
mesh_terms: D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000276:immunology*; D015703:Antigens, CD / Q000096:biosynthesis*; D000943:Antigens, Differentiation / Q000096:biosynthesis; D000944:Antigens, Differentiation, B-Lymphocyte / Q000096:biosynthesis; D016175:B-Lymphocyte Subsets / Q000187:drug effects / Q000276:immunology*; D018956:CD5 Antigens; D002470:Cell Survival; D005786:Gene Expression Regulation / Q000187:drug effects; D007072:Immunoglobulin D / Q000096:biosynthesis; D007075:Immunoglobulin M / Q000276:immunology; D007152:Immunologic Capping; D007156:Immunologic Memory; D015850:Interleukin-6 / Q000494:pharmacology; D008070:Lipopolysaccharides; D008213:Lymphocyte Activation / Q000187:drug effects; D008211:Lymphocyte Cooperation; D051379:Mice; D010641:Phenotype; D011947:Receptors, Antigen, B-Cell / Q000096:biosynthesis; D011961:Receptors, Fc / Q000096:biosynthesis; D017455:Receptors, IgE; D016201:Receptors, Lymphocyte Homing / Q000096:biosynthesis; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology
chemical_list: D000888:Antibodies, Anti-Idiotypic; D015703:Antigens, CD; D000943:Antigens, Differentiation; D000944:Antigens, Differentiation, B-Lymphocyte; D018956:CD5 Antigens; D007072:Immunoglobulin D; D007075:Immunoglobulin M; D015850:Interleukin-6; D008070:Lipopolysaccharides; D011947:Receptors, Antigen, B-Cell; D011961:Receptors, Fc; D017455:Receptors, IgE; D016201:Receptors, Lymphocyte Homing